# OPM Biosciences

> Shanghai-founded OPM Biosciences sells chemically defined cell culture media and custom formulation services, then follows biologic drug programs into contract development and manufacturing. Its recent biosimilar offering joins media optimization to analytical comparability and GMP production.

- **Founded:** 2013
- **Headquarters:** Shanghai, China
- **Founders:** Zhihua Xiao (Founder, chairman and CEO of Shanghai OPM Biosciences)
- **Products:** OPM-CHO media, feeds and supplements, Custom media development and cGMP manufacturing, OPM-CHO media evaluation service, Biosimilar Media Optimization Service, Sureness Biosimilar Platform
- **Notable:** Listed on the Shanghai Stock Exchange STAR Market on September 2, 2022 (688293)., Company reports more than 390 molecules using OPM products at IND, clinical or commercial stages., Company reports an average 96% titer improvement across 35 side-by-side OPM-CHO evaluations, versus each program’s original medium.

## Products & services

- **OPM-CHO media, feeds and supplements** — Chemically defined, animal-origin-free media for CHO cell lines, including AltairCHO, SagiCHO, StarCHO and VegaCHO, with matching feeds and supplements.
- **Custom media development and cGMP manufacturing** — Formulation, screening, bioreactor validation and transfer into dry-powder or liquid media production.
- **OPM-CHO media evaluation service** — Benchmarks catalog media and feeds against a customer process and ranks them against agreed performance criteria.
- **Biosimilar Media Optimization Service** — Molecule-specific formulation work intended to improve titer and align critical quality attributes with a reference biologic.
- **Sureness Biosimilar Platform** — CDMO support from reference-product assessment through cell line and process development, analytical comparability, GMP manufacturing and IND filing support.
- **PharmaLegacy CRO services** — Preclinical pharmacology, screening, DMPK and safety services through a subsidiary.

## Achievements

- Listed on the Shanghai Stock Exchange STAR Market on September 2, 2022 (688293).
- Company reports more than 390 molecules using OPM products at IND, clinical or commercial stages.
- Company reports an average 96% titer improvement across 35 side-by-side OPM-CHO evaluations, versus each program’s original medium.
- ISO 9001:2015-certified quality management system.

## Latest updates

- **2026-09** — Launched Biosimilar Media Optimization Service and the Sureness Biosimilar Platform.
- **2026-01** — Welcomed PharmaLegacy to add CRO capabilities to its media and CDMO business.

## Links

- Website: https://opmbio.com/
- LinkedIn: https://www.linkedin.com/company/opm-bio/

---

Profile page: https://yespress.io/opm-biosciences
Published by YesPress — https://yespress.io
Last updated: 2026-09-28